Cytek Biosciences, Inc. Stock Price, News & Analysis

Cytek Biosciences (Nasdaq: CTKB) announced on November 6, 2025 that its Cytek Muse Micro cell analyzer won Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.

The award recognizes the Muse Micro as an affordable, compact, and intuitive flow cytometry platform that builds on the legacy of the original Guava Muse system. Applications cited include cell counting, viability, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis. The company said the system aims to lower technical and financial barriers for smaller labs and resource-limited facilities.

Cytek Biosciences (Nasdaq: CTKB) announced investor conference participation and investor meetings in November–December 2025. Key events include UBS Global Healthcare Conference (Palm Beach) with 1x1 meetings on Nov 11, 2025, a Stephens NASH25 fireside chat on Nov 19, 2025 at 9:00 a.m. PT / 12:00 p.m. ET, and a Piper Sandler 37th Annual Healthcare fireside chat on Dec 3, 2025 at 6:00 a.m. PT / 9:00 a.m. ET.

Live and archived webcasts for the Stephens and Piper Sandler presentations will be available on the company investor website at investors.cytekbio.com.

Cytek Biosciences (NASDAQ: CTKB) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $52.3M, up 2% year-over-year, with total installed base at 3,456 instruments (added 161 units). Total recurring revenue rose 19% and revenue from biotech/pharma/CRO customers grew 14%. GAAP gross profit was $27.6M and GAAP gross margin was 53% (adjusted gross margin 55% vs 60% prior year). Operating expenses increased 10% and G&A rose 47% due to litigation-related costs and a $0.7M one-time write-off. Net loss was $5.5M versus net income of $0.9M in Q3 2024. Adjusted EBITDA was $2.5M. Cash and marketable securities totaled $261.7M. Full‑year 2025 revenue guidance reaffirmed at $196M–$205M.

Cytek Biosciences (NASDAQ: CTKB) announced a two-part initiative to expand global access to flow cytometry, partnering with the International Society for Advancement of Cytometry (ISAC).

Phase one awards a three-laser Cytek Northern Lights full spectrum flow cytometer to an eligible lab. Phase two will launch a merit-based research grant program overseen by Cytek’s scientific advisory board, expected to debut in conjunction with CYTO 2026. The company cited prior collaboration with ISAC, including a donated Northern Lights system to a laboratory in Salta, Argentina, as an example of impact.

Cytek framed the effort as expanding scientific equity by supporting under-resourced labs and enabling broader access to high-parameter immune monitoring and translational research.

Cytek Biosciences (Nasdaq: CTKB) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.

The company said management will host a webcasted conference call on November 5, 2025 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook. Live audio will be available on the Investors section of the company website at investors.cytekbio.com.

Cytek Biosciences (Nasdaq: CTKB) announced it has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District effective Oct 15, 2025. The site expands Cytek's European footprint by more than 40% and houses offices, an enlarged warehouse, and a dedicated customer service and training center with a fully functional lab for hands-on training on Cytek's Full Spectrum Profiling™ (FSP®) technology.

The company cited strong reagent-business performance as a key driver and has transitioned warehouse operations in-house to improve quality control, operational agility, and turnaround times across EMEA.

Cytek Biosciences (NASDAQ:CTKB), a leader in spectral flow cytometry, will showcase its advanced cell analysis solutions at two major clinical conferences: ESCCA 2025 (September 17-20 in Montpellier, France) and ICCS 2025 (September 28-30 in Philadelphia).

The company's Full Spectrum Profiling™ (FSP®) technology has gained significant traction, with over 2,800 peer-reviewed publications citing its use. The technology enables profiling of more than 40 markers in a single tube, enhancing efficiency and reducing analysis time.

At both conferences, experts will present workshops on integrating spectral flow cytometry with machine learning for improved leukemia and lymphoma diagnosis, demonstrating the technology's practical applications in clinical settings.

Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.

The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.

Cytek Biosciences (Nasdaq: CTKB) reported Q2 2025 financial results, with total revenue of $45.6 million, marking a 2% decrease from Q2 2024. The company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025. Notable highlights include the launch of the Cytek Aurora™ Evo system and 16% growth in recurring revenue, which now accounts for 32% of trailing 12-month revenue.

The company reported a net loss of $5.6 million and Adjusted EBITDA of $1.3 million. Cash position remained strong at $262.0 million. Cytek repurchased $4.5 million of common stock during Q2 and narrowed its 2025 revenue guidance to $196-205 million, projecting -2% to +2% growth over 2024.